|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Strain improve- ment of recombinant Escherichia coli for efficient produc- tion of plant flavonoids 显示文摘 | Leonard E Yan Y Fowler Z L | 2008 | Molecular Pharmaceutics2008，5，2： | 1 |
| 2 | High-yield resveratrol production in engineered Escherichia coli显示文摘 | Lim C G Fowler Z L Hueller T | 2011 | Appl Environ Microbiol2011，77，10： | 1 |
| 3 | Increased malonyl coenzyme A biosynthesis by tuning the Esche- richia coli metabolic network and its application to flava- none production显示文摘 | Fowler Z L Gikandi W W Koffas M A G | 2009 | Applied and Environmental Micro- biology2009，75，18： | 1 |
| 4 | Genome- scale metabolic network modeling results in minimal in- terventions that cooperatively force carbon flux towards malonyl-CoA 显示文摘 | Xu Peng Ranganathan S Fowler Z L | 2011 | Metabolic Engineering2011，13，5： | 1 |
| 5 | Comparative and demographic analysis of orangutan genomes显示文摘 | Locke DP Hillier LW Warren WC Worley KC Nazareth LV Muzny DM Yang SP Wang Z Chinwalla AT Minx P Mitreva M Cook L Delehaunty KD Fronick C Schmidt H Fulton LA Fulton RS Nelson JO Magrini V Pohl C Graves TA Markovic C Cree A Dinh HH Hume J Kovar CL Fowler GR | | 0，，： | 1 |
| 6 | High-yield resveratrol production in engineered Escherichia coli显示文摘 | Lim C G Fowler Z L Hueller T | 2011 | Appl Environ Microbiol2011，77，10： | 1 |
| 7 | High-yield res- veratrol production in engineered Escherichia coli 显示文摘 | Lim C G Fowler Z L Hueller T | 2011 | Applied and Environmental Microbiology2011，77，10： | 1 |
| 8 | Canopy light environment and yield of Narrow-row cotton as affected by canopy architecture显示文摘 | RETA-SANCHEZ D Z Fowler J L | 2002 | Agron J2002，94，： | 1 |
| 9 | Biosynthesis and biotechnologi- cal production of flavanones: Current state and perspectives显示文摘 | Fowler Z L Koffas M A G | 2009 | Applied Microbiology and Biotechnology2009，83，5： | 1 |
| 10 | Genome - scale metabolic network modeling results in minimal interventions that co- operatively force carbon flux towards malonyl - CoA显示文摘 | Xu P Ranganathan S Fowler Z L | 2011 | Metab Eng2011，13，5： | 1 |
| 11 | Improving NADPH availability for natural product biosynthesis in Escherichia coli by metabolic engineering显示文摘 | Chemler J A Fowler Z L McHugh K P | 2010 | Metabolic Engineering2010，12，2： | 1 |
| 12 | Strain improvement of recombinant Escherichia coil for efficient production of plant fiavonoids显示文摘 | Leonard E Yah Y Fowler Z L | 2008 | Mol Pharm2008，5，2： | 1 |
| 13 | Increased malonyl coenzyme a biosynthesis by tuning the Escherichia coli metabolic network and itsapplication to flavanone production显示文摘 | Fowler Z L Gikandi W W Koffas M A | 2009 | Appl Microbiol Biotechnol2009，75，18： | 1 |
| 14 | Develop- ment of non-natural flavanones as antimicrobial agents 显示文摘 | Fowler Z L Shah K Panepinto J C | 2011 | PLoS ONE2011，6，25： | 1 |
| 15 | Biosynthesis and biotechnological production of flavanones:current state and perspectives 显示文摘 | Fowler Z L Koffas M A | 2009 | Applied Microbiology and Biotechnology2009，83，5： | 1 |
| 16 | Strain improvement of recombinant Escherichia coil for efficient production of plant flavonoids显示文摘 | Leonard E Yan Y Fowler Z L | 2008 | Molecular Pharmaceutics2008，5，2： | 1 |
| 17 | Human IgG1 antibodies suppress angiogenesis in a target-independent manner显示文摘Aberrant angiogenesis is implicated in diseases affecting nearly 10%of the world’s population.The most widely used antiangiogenic drug is bevacizumab,a humanized IgG1 monoclonal antibody that targets human VEGFA.Although bevacizumab does not recognize mouse Vegfa,it inhibits angiogenesis in mice.Here we show bevacizumab suppressed angiogenesis in three mouse models not via Vegfa blockade but rather Fc-mediated signaling through FcγRI(CD64)and c-Cbl,impairing macrophage migration.Other approved humanized or human IgG1 antibodies without mouse targets(adalimumab,alemtuzumab,ofatumumab,omalizumab,palivizumab and tocilizumab),mouse IgG2a,and overexpression of human IgG1-Fc or mouse IgG2a-Fc,also inhibited angiogenesis in wild-type and FcγR humanized mice.This anti-angiogenic effect was abolished by Fcgr1 ablation or knockdown,Fc cleavage,IgG-Fc inhibition,disruption of Fc-FcγR interaction,or elimination of FcRγ-initated signaling.Furthermore,bevacizumab’s Fc region potentiated its anti-angiogenic activity in humanized VEGFA mice.Finally,mice deficient in FcγRI exhibited increased developmental and pathological angiogenesis.These findings reveal an unexpected anti-angiogenic function for FcγRI and a potentially concerning off-target effect of hIgG1 therapies. | Sasha Bogdanovich Younghee Kim Takeshi Mizutani Reo Yasuma Laura Tudisco Valeria Cicatiello Ana Bastos-Carvalho Nagaraj Kerur Yoshio Hirano Judit Z Baffi Valeria Tarallo Shengjian Li Tetsuhiro Yasuma Parthasarathy Arpitha Benjamin J Fowler Charles B Wright Ivana Apicella Adelaide Greco Arturo Brunetti Menotti Ruvo Annamaria Sandomenico Miho Nozaki Ryo Ijima Hiroki Kaneko Yuichiro Ogura Hiroko Terasaki Balamurali K Ambati Jeanette HW Leusen Wallace Y Langdon Michael R Clark Kathryn L Armour Pierre Bruhns J Sjef Verbeek Bradley D Gelfand Sandro De Falco Jayakrishna Ambati | 2016 | Signal Transduction and Targeted Therapy2016，1，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员